Janssen Receives CHMP Positive Opinion For Guselkumab Recommending Approval For The Treatment Of Moderate To Severe Plaque Psoriasis In The European Union
- EMEA Innovative Medicine
- Janssen Receives CHMP Positive Opinion For Guselkumab Recommending Approval For The Treatment Of Moderate To Severe Plaque Psoriasis In The European Union
Janssen Receives CHMP Positive Opinion For Guselkumab Recommending Approval For The Treatment Of Moderate To Severe Plaque Psoriasis In The European Union
- X (Twitter)
Copy link